Stephen Marcus | Chief Executive Officer
Cantex Pharmaceuticals

Stephen Marcus, Chief Executive Officer, Cantex Pharmaceuticals

Stephen Marcus, M.D., is a medical oncologist and pharmaceutical executive who has led the development of several profitable pharmaceutical and biotechnology products. Dr. Marcus led the development of Betaseron, the first effective treatment for multiple sclerosis, and was instrumental in the development of Intron A, Temodar, Fludara, and brand-equivalent Paclitaxel. Dr. Marcus is the Chief Executive Officer of Cantex Pharmaceuticals, a clinical stage pharmaceutical company dedicated and committed to its mission to develop proprietary compounds that enhance the efficacy and safety of the treatment of cancers and blood disorders, while reducing the life-threatening side effects of such treatments.

back to speakers